Company news

Satellos Bioscience Inc news in 2025

Satellos Bioscience Inc's news releases, calls and decks from 2025, newest first.

View company

Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy

December 9, 2025

Satellos to Participate in December Investor Conferences

November 25, 2025

Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy

November 18, 2025

Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors

November 14, 2025

Satellos to Participate in November Investor Conferences

October 30, 2025

Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy

October 21, 2025

Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy

October 10, 2025

Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress

September 29, 2025

Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy

September 22, 2025

Sitryx appoints Adam Mostafa as Chief Financial Officer

September 8, 2025

Satellos to Participate in Four September Institutional and Retail Investor Conferences

August 21, 2025

Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones

August 13, 2025

Satellos to Present at Canaccord Genuity’s 45th Annual Growth Conference

August 5, 2025

Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer

July 16, 2025

Satellos Bioscience Shareholders Elect Two New Board Members

June 18, 2025

Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders

June 18, 2025

Satellos Bioscience to Participate in PPMD’s Annual Conference in Las Vegas

June 16, 2025

Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy

May 22, 2025

Bloom Burton & Co. Inc. Announces Exercise of Satellos Bioscience Inc. Warrants

May 20, 2025

Satellos Reports First Quarter 2025 Results and Highlights Recent Company Progress

May 13, 2025

Satellos to Present at the CureDuchenne FUTURES National Conference

May 7, 2025

Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference

April 29, 2025

Satellos to Participate in Two April Investor Conferences

April 2, 2025

Satellos Reports 2024 Financial Results and Highlights Company Progress

March 26, 2025

Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

March 19, 2025

Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

February 18, 2025

Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers

February 10, 2025

Decks in 2025